Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
DNP – Die Neurologie & Psychiatrie
Erschienen in: DNP - Der Neurologe & Psychiater 3/2012

29.02.2012 | Fortbildung

Wo stehen wir nach 100 Jahren mit L-Dopa?

Morbus Parkinson

Erschienen in: DNP – Die Neurologie & Psychiatrie | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Einführung von L-Dopa in die Parkinsonbehandlung ist ein Lehrbeispiel für die konsequente Entwicklung eines Medikaments, von der Kenntnis eines neuropathologisch/biochemischen Defekts bis zum hochwirksamen Therapieprinzip. So wurde L-Dopa 1977 in die WHO-Liste der unentbehrlichen Medikamente aufgenommen. Aber selbst 50 Jahre nach der Erstbeschreibung der therapeutischen Wirksamkeit dieser Substanz und trotz ihres unbestrittenen hohen Potenzials bleiben ungelöste Schwierigkeiten in der Langzeitbehandlung, neue Probleme der L-Dopa-Therapie sind hinzugekommen.

Literatur
  1. Arnulf I, Leu-Semenescu S. Sleepiness in Parkinson’s disease. Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S101–4.PubMedView Article
  2. Baas H, Zehrden F, Selzer R, Kohnen R, Loetsch J, Harder S. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson’s disease. Clin Pharmacokinet. 2001;40(5):383–93.PubMedView Article
  3. Barbeau A, Murphy GF, Sourkes TL. Excretion of dopamine in diseases of basal ganglia. Science. 1961 May 26;133(3465):1706–7.PubMedView Article
  4. Bergemann N, Baas H, Fischer PA. [Slow-release L-dopa vs. standard L-dopa in Parkinson patients in various stages of the disease. Studies of pharmacokinetics and motor effectiveness]. Nervenarzt. 1994 Apr;65(4):250–7.PubMed
  5. Bertler A, Rosengren E. Occurrence and distribution of catechol amines in brain. Acta Physiol Scand. 1959 Dec 12;47:350–61.PubMed
  6. Birkmayer W, Hornykiewicz O. [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. Wien Klin Wochenschr. 1961 Nov 10;73:787–8.PubMed
  7. Birkmayer W. [Experimental results of the combined treatment of parkinsonism using L-DOPA and a decarboxylase inhibitory agent (Ro 4-4602)]. Wien Klin Wochenschr. 1969 Sep 26;81(39):677–9.PubMed
  8. Bloch F, Houeto JL, Tezenas du Montcel S, Bonneville F, Etchepare F, Welter ML, Rivaud-Pechoux S, Hahn-Barma V, Maisonobe T, Behar C, Lazennec JY, Kurys E, Arnulf I, Bonnet AM, Agid Y. Parkinson’s disease with camptocormia. J Neurol Neurosurg Psychiatry. 2006 Nov;77(11):1223–8.PubMedView Article
  9. Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL; PKDS009 Study Group. The long-acting dopamine receptor agonist cabergoline in early Parkinson’s disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs. 2004;18(11):733–46.View Article
  10. Buhmann C, Klucken J, Korchounov A, Schwarz M, Vieregge P, Jost WH. [When should we start medical treatment in Parkinson disease]. Fortschr Neurol Psychiatr. 2010 Mar;78 Suppl 1:S31–3.PubMedView Article
  11. Carlsson A, Lindquist M, Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature. 1957 Nov 30;180(4596):1200.PubMedView Article
  12. Carlsson A, Lindqvist M, Magnusson T, Waldeck B. On the presence of 3-hydroxytyramine in brain. Science. 1958 Feb 28;127(3296):471.PubMedView Article
  13. Clarke CE, Patel S, Ives N, Rick C, Wheatley K, Gray R. Should treatment for Parkinson’s disease start immediately on diagnosis or delayed until functional disability develops? Mov Disord. 2011 Jun;26(7):1187–93.PubMedView Article
  14. Constantinescu R, Romer M, McDermott MP, Kamp C, Kieburtz K; CALM-PD Investigators of the Parkinson Study Group. Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov Disord. 2007 Jul 15;22(9):1317–9.PubMedView Article
  15. Contin M, Martinelli P. Pharmacokinetics of levodopa. J Neurol. 2010; 257 (Suppl 2): S253–261PubMedView Article
  16. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967 Feb 16;276(7):374–9.PubMedView Article
  17. Degkwitz R, Frowein R, Kulenkampff C, Mohs U. [On the effects of L-dopa in man and their modification by reserpine, chlorpromazine, iproniazid and vitamin B6]. Klin Wochenschr. 1960 Feb 1;38:120–3.PubMedView Article
  18. Dupont E, Andersen A, Boas J, Boisen E, Borgmann R, Helgetveit AC, Kjaer MO, Kristensen TN, Mikkelsen B, Pakkenberg H, Presthus J, Stien R, Worm-Petersen J, Buch D. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand. 1996 Jan;93(1):14–20.PubMedView Article
  19. Duvoisin RC. Variations in the “on-off” phenomenon. Adv Neurol. 1974;5:339–40.PubMed
  20. Eggert C, Oertel WH, Deuschl G Diagnostik und Therapie des Parkinson-Syndroms. Leitlinien der AWMF, Version 2011 in Vorbereitung: www.​awmf.​org
  21. Ehringer H, Hornikiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. Klin Wochenschr. 1960 Dec 15;38:1236–9.PubMedView Article
  22. Espay AJ, Fasano A, van Nuenen BF, Payne MM, Snijders AH, Bloem BR. „On“ state freezing of gait in Parkinson disease: A paradoxical levodopa-induced complication. Neurology. 2012 Jan 18. [Epub ahead of print]
  23. Evans AH, Lawrence AD, Cresswell SA, Katzenschlager R, Lees AJ. Compulsive use of dopaminergic drug therapy in Parkinson’s disease: reward and anti-reward. Mov Disord. 2010 May 15;25(7):867–76.PubMedView Article
  24. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004 Dec 9;351(24):2498–508.PubMedView Article
  25. Fahn S. The history of dopamine and levodopa in the treatment of Parkinson’s disease. Mov Disord. 2008;23 Suppl 3:S497–508.PubMedView Article
  26. Fénelon G, Alves G. Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci. 2010 Feb 15;289(1–2):12–7.PubMedView Article
  27. Fischer PA, Schneider E, Jacobi P, Maxion H. [Combination therapy of Parkinson’s syndrome using L-dopa and a decarboxylase inhibitor]. Med Welt. 1973 Nov 9;24(45):1742–6PubMed
  28. Fischer PA, Schneider E, Jacobi P, Maxion H. [Longtime study on the effects of L-dopa therapy in parkinsonism]. Nervenarzt. 1973 Mar;44(3):128–35.PubMed
  29. Fisone G, Bezard E. Molecular mechanisms of l-DOPA-induced dyskinesia. Int Rev Neurobiol. 2011;98:95–122.PubMedView Article
  30. Forsaa EB, Larsen JP, Wentzel-Larsen T, Goetz CG, Stebbins GT, Aarsland D, Alves G. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010 Aug;67(8):996–1001.PubMedView Article
  31. Gao J, Huang X, Park Y, Hollenbeck A, Blair A, Schatzkin A, Chen H. Daytime napping, nighttime sleeping, and Parkinson disease. Am J Epidemiol. 2011 May 1;173(9):1032–8.PubMedView Article
  32. García de Yébenes J, Mateo D, Pino MA, Cordero M, Pastor M, Chacón J, Morales B, Sánchez V, Mena MA, Giménez Roldán S. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients]. Neurologia. 1997 Apr;12(4):145–56.PubMed
  33. Harder S, Baas H, Bergemann N, Demisch L, Rietbrock S. Concentration-effect relationship of levodopa in patients with Parkinson’s disease after oral administration of an immediate release and a controlled release formulation. Br J Clin Pharmacol. 1995 Jan;39(1):39–44.PubMed
  34. Harder S, Baas H. Concentration-response relationship of levodopa in patients at different stages of Parkinson’s disease. Clin Pharmacol Ther. 1998 Aug;64(2):183–91.PubMedView Article
  35. Hauser RA, Auinger P, Oakes D; Parkinson Study Group. Levodopa response in early Parkinson’s disease. Mov Disord. 2009 Dec 15;24(16):2328–36.PubMed
  36. Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE. Ten-year follow-up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord. 2007 Dec;22(16):2409–17.PubMedView Article
  37. Hauser RA. New considerations in the medical management of early Parkinson’s disease: impact of recent clinical trials on treatment strategy. Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S17–21.PubMedView Article
  38. Hornykiewicz O. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent. Amino Acids. 2002;23(1–3):65–70.PubMedView Article
  39. Inzelberg R, Schechtman E, Nisipeanu P. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson’s disease: an evidence-based comparison. Drugs Aging. 2003;20(11):847–55.PubMedView Article
  40. Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ; Parkinson’s Disease Research Group of the United Kingdom. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology. 2008 Aug 12;71(7):474–80.PubMedView Article
  41. Knie B, Mitra MT, Logishetty K, Chaudhuri KR. Excessive daytime sleepiness in patients with Parkinson’s disease. CNS Drugs. 2011 Mar;25(3):203–12.PubMedView Article
  42. Kondo T. Levodopa therapy from the neuroprotection viewpoint. From a clinical outlook. J Neurol. 2005 Oct;252 Suppl 4:IV32–IV36.PubMedView Article
  43. Kulisevsky J, Pagonabarraga J. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson’s disease: meta-analysis of randomized controlled trials. Drug Saf. 2010 Feb 1;33(2):147–61.PubMedView Article
  44. Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology. 2001 Nov 13;57(9):1687–94.PubMed
  45. Lim A, Leow L, Huckabee ML, Frampton C, Anderson T. A pilot study of respiration and swallowing integration in Parkinson’s disease: „on“ and „off“ levodopa. Dysphagia. 2008 Mar;23(1):76–81.PubMedView Article
  46. López IC, Ruiz PJ, Del Pozo SV, Bernardos VS. Motor complications in Parkinson’s disease: ten year follow-up study. Mov Disord. 2010 Dec 15;25(16):2735–9PubMedView Article
  47. Melamed E, Djaldetti R. Camptocormia in Parkinson’s disease. J Neurol. 2006 Dec;253 Suppl 7:VII14–16..PubMedView Article
  48. Mena MA, Casarejos MJ, García de Yébenes J. The effect of glia-conditioned medium on dopamine neurons in culture. Modulation of apoptosis, tyrosine hydroxylase expression and 1-methyl-4-phenylpyridinium toxicity. J Neural Transm. 1999;106(11–12):1105–23.PubMedView Article
  49. Menezes C, Melo A. Does levodopa improve swallowing dysfunction in Parkinson’s disease patients? J Clin Pharm Ther. 2009 Dec;34(6):673–6.PubMedView Article
  50. Morrish PK. How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson’s disease? Mov Disord. 2003 Oct;18 Suppl 7:S63–70.PubMedView Article
  51. Mytilineou C, Han SK, Cohen G. Toxic and protective effects of L-dopa on mesencephalic cell cultures. J Neurochem. 1993 Oct;61(4):1470–8.PubMedView Article
  52. Nowak P, Kostrzewa RA, Skaba D, Kostrzewa RM. Acute L-DOPA effect on hydroxyl radical- and DOPAC-levels in striatal microdialysates of parkinsonian rats. Neurotox Res. 2010 Apr;17(3):299–304.PubMedView Article
  53. Nyholm D, Askmark H, Gomes-Trolin C, Knutson T, Lennernäs H, Nyström C, Aquilonius SM. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol. 2003 May-Jun;26(3):156–63.PubMedView Article
  54. Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, Aquilonius SM, Askmark H. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005 Jan 25;64(2):216–23.PubMedView Article
  55. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E; ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med. 2009 Sep 24;361(13):1268–78.PubMedView Article
  56. O’sullivan SS, Evans AH, Lees AJ. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs. 2009;23(2):157–70.PubMedView Article
  57. Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol. 2009 May;66(5):563–70.View Article
  58. Rajput AH, Uitti RJ, Rajput A, Offord KP. Mortality in Parkinson’s disease. Mov Disord. 2010 Mar 15;25(4):507–8..PubMedView Article
  59. Rajput AH. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord. 2001 Oct;8(2):95–100.PubMedView Article
  60. Ravina B, Eidelberg D, Ahlskog JE, Albin RL, Brooks DJ, Carbon M, Dhawan V, Feigin A, Fahn S, Guttman M, Gwinn-Hardy K, McFarland H, Innis R, Katz RG, Kieburtz K, Kish SJ, Lange N, Langston JW, Marek K, Morin L, Moy C, Murphy D, Oertel WH, Oliver G, Palesch Y, Powers W, Seibyl J, Sethi KD, Shults CW, Sheehy P, Stoessl AJ, Holloway R. The role of radiotracer imaging in Parkinson disease. Neurology. 2005 Jan 25;64(2):208–15.PubMedView Article
  61. Reuter I, Harder S, Engelhardt M, Baas H. The effect of exercise on pharmacokinetics and pharmacodynamics of levodopa. Mov Disord. 2000 Sep;15(5):862–8.PubMedView Article
  62. Sano I, Gamo T, Kakimoto Y, Taniguchi K, Takesada M, Nishinuma K. Distribution of catechol compounds in human brain. Biochim Biophys Acta. 1959 Apr;32:586–7.PubMedView Article
  63. Sano I, Taniguchi K, Gamo T, Takesada M, Kakimoto Y. [The catecholamines in the central nervous system]. Klin Wochenschr. 1960 Jan 15;38:57–62.PubMedView Article
  64. Schapira AH. The clinical relevance of levodopa toxicity in the treatment of Parkinson’s disease. Mov Disord. 2008;23 Suppl 3:S515–20.PubMedView Article
  65. Schneider E, Fischer PA, Jacobi P, Maxion H. [Comparison of the effect of L-Dopa and of an L-Dopa+decarboxylase inhibitor combination in Parkinson’s disease]. Arch Psychiatr Nervenkr. 1973 Mar 19;217(1):95–112.PubMedView Article
  66. Schneider E, Fischer PA, Jacobi P. [Sustained levodopa efficacy in parkinsonism. Results of a four-year long-term follow-up study (author’s transl)]. Nervenarzt. 1977 Apr;48(4):205–10.PubMed
  67. Schroeteler F, Ziegler K, Fietzek UM, Ceballos-Baumann A. [Freezing of gait: phenomenology, pathophysiology, and therapeutic approaches]. Nervenarzt. 2009 Jun;80(6):693–9.PubMedView Article
  68. Seki M, Takahashi K, Koto A, Mihara B, Morita Y, Isozumi K, Ohta K, Muramatsu K, Gotoh J, Yamaguchi K, Tomita Y, Sato H, Nihei Y, Iwasawa S, Suzuki N; on behalf of Keio Parkinson’s Disease Database. Camptocormia in Japanese patients with Parkinson’s disease: A multicenter study. Mov Disord. 2011 Dec;26(14):2567–2571.PubMedView Article
  69. Sharma JC, Ross IN, Rascol O, Brooks D. Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight. Eur J Neurol. 2008 May;15(5):493–6.PubMedView Article
  70. Simuni T, Stern MB. Does levodopa accelerate Parkinson’s disease? Drugs Aging. 1999 Jun;14(6):399–408.PubMedView Article
  71. Sung YH, Chung SJ, Kim SR, Lee MC. Factors predicting response to dopaminergic treatment for resting tremor of Parkinson’s disease. Mov Disord. 2008 Jan;23(1):137–40.PubMedView Article
  72. Walker RW, Howells AR, Gray WK. The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson’s disease. Parkinsonism Relat Disord. 2011 Jan;17(1):27–9.PubMedView Article
  73. Waters C. Did levodopa vs. dopamine agonist trials teach us when and how to start symptomatic therapy? Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S31–3.PubMedView Article
  74. Weintraub D. Impulse control disorders in Parkinson’s disease: prevalence and possible risk factors. Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S110–3.PubMedView Article
  75. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol. 1969 Oct;21(4):343–54.PubMedView Article
  76. Zesiewicz TA. Parkinson disease: The controversy of levodopa toxicity in Parkinson disease. Nat Rev Neurol. 2011 Dec 26;8(1):8–10.PubMedView Article
  77. Ziegler M, Castro-Caldas A, Del Signore S, Rascol O. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson’s disease: a 6-month, randomized, placebo-controlled study. Mov Disord. 2003 Apr;18(4):418–25.PubMedView Article
Metadaten
Titel
Wo stehen wir nach 100 Jahren mit L-Dopa?
Morbus Parkinson
Publikationsdatum
29.02.2012
Erschienen in
DNP – Die Neurologie & Psychiatrie / Ausgabe 3/2012
Print ISSN: 2731-8168
Elektronische ISSN: 2731-8176
DOI
https://doi.org/10.1007/s15202-012-0127-x

Weitere Artikel der Ausgabe 3/2012

DNP - Der Neurologe & Psychiater 3/2012 Zur Ausgabe

Pharmaforum

Aktive Mitarbeit der MS-Patienten anstreben

Literatur kompakt

Muskuloskelettale Probleme bei professionellen Orchestermusikern

Praxis konkret

Auch beim Schlaganfall ist Prävention Trumpf

Pharmaforum

Positive Langzeitdaten für Rotigotin beim RLS

Praxis konkret

Datenschutzfalle Praxismonitor

Editorial

Ein bisschen wie Alice im Wunderland

Neu in den Fachgebieten Neurologie und Psychiatrie

23.04.2024 | Demenz | Nachrichten

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 | Parkinson-Krankheit | Podcast | Nachrichten

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus
Professorin Dr. Claudia Trenkwalder, Neurologin

23.04.2024 | Depression antepartal oder postpartal | Nachrichten

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

22.04.2024 | DGIM 2024 | Nachrichten

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein